Company: INMB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001213900-25-073077
Chunk: 18

Company: Inmune Bio, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 18
---
5 – FAIR VALUE MEASUREMENTS

The following table presents the hierarchy
for assets and liabilities measured at fair value on a recurring basis:

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    June 30, 2025: 

    Cash equivalents 

    Money market funds 
    $32,919  
    $32,919  
    $          -  
    $          - 
  
    Total cash equivalents 
    $32,919  
    $32,919  
    $-  
    $- 

    (in thousands) 
    Total  
    Quoted Price in Active Market (Level 1)  
    Significant Other Observable Inputs (Level 2)  
    Significant Unobservable Inputs  (Level 3) 
  
    December 31, 2024: 

    Cash equivalents 

    Treasury Bills 
    $10,260  
    $10,260  
    $          -  
    $          - 
  
    Money market fund 
     10,328  
     10,328  
     -  
     - 
  
    Total cash equivalents 
    $20,588  
    $20,588  
    $-  
    $- 

NOTE 6 – COMMITMENTS 

In April
2025, the Company wholly owned subsidiary, INmune Bio International Ltd., entered into an agreement whereby the Company leases manufacturing
space from a third party in the United Kingdom for 2 years. The lease requires payments of approximately $77,000 each quarter during the
first year and $154,000 each quarter during the second year. The lease commencement date is August 2025.

As of June 30, 2025, the maturities
of our lease liabilities are as follows:

    (in thousands, except years) 

    2025 
    $136 
  
    2026 
     278 
  
    2027 
     91 
  
    Total lease payments 
     505 
  
    Less: imputed interest 
     (54)
  
    Present value of future lease payments 
     451 
  
    Less: operating lease, current